Acurx Pharmaceuticals, Inc.
ACXPHealthcare|Biotechnology|US
$1.06
+0.11 (+12.09%)
DCF Value
$5.07
Tangible Book / Share
$1.91
Cash / Share
$2.50
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07513285 ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection | Clostridium Difficile Infection Recurrence | P2 | Recruiting | 20 | Open-label | Ibezapolstat |
| NCT04247542 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection | Clostridium Difficile Infection | P2 | Completed | 53 | RCT, Double-blind | Ibezapolstat, Vancomycin |